Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Receives Consensus Recommendation of “Strong Buy” from Brokerages

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price target of $12.25 for the company and are anticipating that the company will post $0.11 earnings per share for the current quarter, according to Zacks. Zacks has also given Cumberland Pharmaceuticals an industry rank of 71 out of 255 based on the ratings given to its competitors.

Several equities analysts recently issued reports on CPIX shares. ValuEngine cut Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Zacks Investment Research upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Wednesday, August 21st.

In related news, Director Gordon R. Bernard sold 6,309 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $5.46, for a total value of $34,447.14. Following the transaction, the director now owns 41,862 shares in the company, valued at $228,566.52. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders purchased 4,375 shares of company stock worth $25,050 and sold 33,169 shares worth $179,035. 39.38% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Financial Gravity Wealth Inc. bought a new position in Cumberland Pharmaceuticals during the third quarter worth about $36,000. Acadian Asset Management LLC boosted its holdings in Cumberland Pharmaceuticals by 6.9% during the second quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock worth $665,000 after buying an additional 6,765 shares during the last quarter. Bailard Inc. bought a new position in Cumberland Pharmaceuticals during the second quarter worth about $92,000. BlackRock Inc. boosted its holdings in Cumberland Pharmaceuticals by 17.2% during the second quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock worth $2,118,000 after buying an additional 48,753 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Cumberland Pharmaceuticals by 13.0% during the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after buying an additional 50,800 shares during the last quarter. Hedge funds and other institutional investors own 31.03% of the company’s stock.

Cumberland Pharmaceuticals stock traded down $0.01 during mid-day trading on Friday, hitting $5.43. The stock had a trading volume of 12,783 shares, compared to its average volume of 19,985. The stock has a 50-day simple moving average of $5.32 and a two-hundred day simple moving average of $5.81. The stock has a market capitalization of $83.61 million, a PE ratio of -45.25 and a beta of 0.16. Cumberland Pharmaceuticals has a 12 month low of $4.70 and a 12 month high of $7.00. The company has a current ratio of 2.33, a quick ratio of 1.85 and a debt-to-equity ratio of 0.37.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Wednesday, August 14th. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.02. The business had revenue of $11.58 million for the quarter, compared to analysts’ expectations of $12.59 million. Cumberland Pharmaceuticals had a positive return on equity of 5.04% and a negative net margin of 9.87%. Sell-side analysts expect that Cumberland Pharmaceuticals will post 0.31 earnings per share for the current fiscal year.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Read More: What does a dividend yield signify to investors?

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.